Nycomed Reviewing Bids For U.S. Partners For Daxas
This article was originally published in The Pink Sheet Daily
Executive Summary
Bidding ended last week for potential U.S. partners for Nycomed’s new COPD drug, and the vetting process is under way.
You may also be interested in...
Daxas Approved In EU With Narrow Indication
Nycomed's drug gets the green light to treat severe COPD with chronic bronchitis in adult patients with a history of frequent exacerbations, as an add-on to bronchodilator treatment.
Daxas Approved In EU With Narrow Indication
Nycomed's drug gets the green light to treat severe COPD with chronic bronchitis in adult patients with a history of frequent exacerbations, as an add-on to bronchodilator treatment.
Merck Puffs Up Respiratory Portfolio With EU Rights To Nycomed's Daxas
Merck acquires rights to the oral COPD medication in Canada and Europe, where approval appears imminent after Daxas received a positive CHMP nod.